FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054241472> ?p ?o ?g. }

• W2054241472 endingPage "447" @default.
• W2054241472 startingPage "438" @default.
• W2054241472 abstract "In a multicenter, double-blind, group comparative trial, the efficacy of nedocromil sodium (nedocromil, 4 mg, four times daily [qid]), cromolyn sodium (2 mg, qid), and placebo was compared in patients receiving inhaled β2-agonists and inhaled corticosteroids for the treatment of chronic reversible obstructive airway disease. After a 2-week baseline period, 132 patients (8 centers) between the ages of 20 and 75 years entered a 4-week run-in period in which the dose of inhaled corticosteroid was reduced by 50 percent. During the run-in phase, deterioration of symptoms (total symptom score) by ten points qualified patients to enter the 6-week drug trial period. Patients in the nedocromil treatment group showed the most robust and consistent improvements over placebo and cromolyn sodium for all daily diary variables. Statistically significant improvements over placebo were noted for both active treatment groups for daytime, nighttime, and total symptom score. Symptom scores for nedocromil were statistically significantly improved over both cromolyn sodium and placebo for both daytime and nighttime asthma. Patients treated with nedocromil also demonstrated a significant reduction in the use of nighttime as needed (prn) β2-agonists as compared with either the placebo- or cromolyn sodium-treated groups. Only nedocromil-treated patients demonstrated a statistically significant improvement in morning peak expiratory Bow rate (PEFR) as compared with placebo. Both nedocromil and cromolyn sodium groups demonstrated statistically significant improvements in afternoon and evening PEFRs. Collectively, the improvements in nighttime symptoms, decreased bronchodilator use, and improved morning PEFR show that patients treated with nedocromil had improved nocturnal symptoms. Pulmonary function tests (FEV1, FVC, PEFR) demonstrated no statistically significant differences between the two active treatments, although trends favored nedocromil for both FEV1 and PEFR. Although symptoms improved in patients treated with cromolyn sodium, the level of symptom control was less than that achieved by nedocromil. As compared with baseline control (regular dose of inhaled steroids), patients treated with nedocromil plus the 50 percent reduced dosage of inhaled corticosteroid consistently demonstrated comparable or better symptom control. Although both active drugs reduced symptoms, nedocromil proved to be more effective than cromolyn sodium for treatment of reversible obstructive airway disease in patients normally well maintained on regimens of low to moderate doses of inhaled corticosteroids. In a multicenter, double-blind, group comparative trial, the efficacy of nedocromil sodium (nedocromil, 4 mg, four times daily [qid]), cromolyn sodium (2 mg, qid), and placebo was compared in patients receiving inhaled β2-agonists and inhaled corticosteroids for the treatment of chronic reversible obstructive airway disease. After a 2-week baseline period, 132 patients (8 centers) between the ages of 20 and 75 years entered a 4-week run-in period in which the dose of inhaled corticosteroid was reduced by 50 percent. During the run-in phase, deterioration of symptoms (total symptom score) by ten points qualified patients to enter the 6-week drug trial period. Patients in the nedocromil treatment group showed the most robust and consistent improvements over placebo and cromolyn sodium for all daily diary variables. Statistically significant improvements over placebo were noted for both active treatment groups for daytime, nighttime, and total symptom score. Symptom scores for nedocromil were statistically significantly improved over both cromolyn sodium and placebo for both daytime and nighttime asthma. Patients treated with nedocromil also demonstrated a significant reduction in the use of nighttime as needed (prn) β2-agonists as compared with either the placebo- or cromolyn sodium-treated groups. Only nedocromil-treated patients demonstrated a statistically significant improvement in morning peak expiratory Bow rate (PEFR) as compared with placebo. Both nedocromil and cromolyn sodium groups demonstrated statistically significant improvements in afternoon and evening PEFRs. Collectively, the improvements in nighttime symptoms, decreased bronchodilator use, and improved morning PEFR show that patients treated with nedocromil had improved nocturnal symptoms. Pulmonary function tests (FEV1, FVC, PEFR) demonstrated no statistically significant differences between the two active treatments, although trends favored nedocromil for both FEV1 and PEFR. Although symptoms improved in patients treated with cromolyn sodium, the level of symptom control was less than that achieved by nedocromil. As compared with baseline control (regular dose of inhaled steroids), patients treated with nedocromil plus the 50 percent reduced dosage of inhaled corticosteroid consistently demonstrated comparable or better symptom control. Although both active drugs reduced symptoms, nedocromil proved to be more effective than cromolyn sodium for treatment of reversible obstructive airway disease in patients normally well maintained on regimens of low to moderate doses of inhaled corticosteroids." @default.
• W2054241472 created "2016-06-24" @default.
• W2054241472 creator A5031645929 @default.
• W2054241472 creator A5038028827 @default.
• W2054241472 creator A5060221815 @default.
• W2054241472 creator A5061381290 @default.
• W2054241472 date "1993-08-01" @default.
• W2054241472 modified "2023-09-27" @default.
• W2054241472 title "Nedocromil Sodium Is More Effective Than Cromolyn Sodium for the Treatment of Chronic Reversible Obstructive Airway Disease" @default.
• W2054241472 cites W1492843278 @default.
• W2054241472 cites W1975474439 @default.
• W2054241472 cites W1978921607 @default.
• W2054241472 cites W1979401819 @default.
• W2054241472 cites W1979794011 @default.
• W2054241472 cites W1981826847 @default.
• W2054241472 cites W1981965711 @default.
• W2054241472 cites W1984968537 @default.
• W2054241472 cites W1985765891 @default.
• W2054241472 cites W1990612727 @default.
• W2054241472 cites W1990951259 @default.
• W2054241472 cites W1994441935 @default.
• W2054241472 cites W1999456396 @default.
• W2054241472 cites W2013028382 @default.
• W2054241472 cites W2013851350 @default.
• W2054241472 cites W2019444582 @default.
• W2054241472 cites W2022082810 @default.
• W2054241472 cites W2024490596 @default.
• W2054241472 cites W2024962352 @default.
• W2054241472 cites W2027880812 @default.
• W2054241472 cites W2028184859 @default.
• W2054241472 cites W2031545075 @default.
• W2054241472 cites W2035976386 @default.
• W2054241472 cites W2037613286 @default.
• W2054241472 cites W2037989587 @default.
• W2054241472 cites W2043158008 @default.
• W2054241472 cites W2046332680 @default.
• W2054241472 cites W2047509209 @default.
• W2054241472 cites W2053338511 @default.
• W2054241472 cites W2057160132 @default.
• W2054241472 cites W2061533407 @default.
• W2054241472 cites W2066606954 @default.
• W2054241472 cites W2066830667 @default.
• W2054241472 cites W2075129738 @default.
• W2054241472 cites W2077902722 @default.
• W2054241472 cites W2090381351 @default.
• W2054241472 cites W2131441125 @default.
• W2054241472 cites W2148568126 @default.
• W2054241472 cites W2182813092 @default.
• W2054241472 cites W2334701948 @default.
• W2054241472 cites W2335673027 @default.
• W2054241472 doi "https://doi.org/10.1378/chest.104.2.438" @default.
• W2054241472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8393398" @default.
• W2054241472 hasPublicationYear "1993" @default.
• W2054241472 type Work @default.
• W2054241472 sameAs 2054241472 @default.
• W2054241472 citedByCount "40" @default.
• W2054241472 countsByYear W20542414722012 @default.
• W2054241472 countsByYear W20542414722013 @default.
• W2054241472 countsByYear W20542414722014 @default.
• W2054241472 crossrefType "journal-article" @default.
• W2054241472 hasAuthorship W2054241472A5031645929 @default.
• W2054241472 hasAuthorship W2054241472A5038028827 @default.
• W2054241472 hasAuthorship W2054241472A5060221815 @default.
• W2054241472 hasAuthorship W2054241472A5061381290 @default.
• W2054241472 hasConcept C126322002 @default.
• W2054241472 hasConcept C142724271 @default.
• W2054241472 hasConcept C19720800 @default.
• W2054241472 hasConcept C204787440 @default.
• W2054241472 hasConcept C27081682 @default.
• W2054241472 hasConcept C2776002719 @default.
• W2054241472 hasConcept C2776042228 @default.
• W2054241472 hasConcept C2776804153 @default.
• W2054241472 hasConcept C2781018748 @default.
• W2054241472 hasConcept C2910070530 @default.
• W2054241472 hasConcept C2911192292 @default.
• W2054241472 hasConcept C42219234 @default.
• W2054241472 hasConcept C71924100 @default.
• W2054241472 hasConceptScore W2054241472C126322002 @default.
• W2054241472 hasConceptScore W2054241472C142724271 @default.
• W2054241472 hasConceptScore W2054241472C19720800 @default.
• W2054241472 hasConceptScore W2054241472C204787440 @default.
• W2054241472 hasConceptScore W2054241472C27081682 @default.
• W2054241472 hasConceptScore W2054241472C2776002719 @default.
• W2054241472 hasConceptScore W2054241472C2776042228 @default.
• W2054241472 hasConceptScore W2054241472C2776804153 @default.
• W2054241472 hasConceptScore W2054241472C2781018748 @default.
• W2054241472 hasConceptScore W2054241472C2910070530 @default.
• W2054241472 hasConceptScore W2054241472C2911192292 @default.
• W2054241472 hasConceptScore W2054241472C42219234 @default.
• W2054241472 hasConceptScore W2054241472C71924100 @default.
• W2054241472 hasIssue "2" @default.
• W2054241472 hasLocation W20542414721 @default.
• W2054241472 hasLocation W20542414722 @default.
• W2054241472 hasOpenAccess W2054241472 @default.
• W2054241472 hasPrimaryLocation W20542414721 @default.
• W2054241472 hasRelatedWork W148179635 @default.
• W2054241472 hasRelatedWork W1968589795 @default.
• W2054241472 hasRelatedWork W1985960529 @default.

• next